お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1006218

短腸症候群市場調査レポート:医薬品クラス別(GLP-2、グルタミン、成長ホルモン)-2026年までの予測-COVID-19の累積的影響

Short Bowel Syndrome Market Research Report by Drug Class (GLP-2, Glutamine, and Growth Hormone), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円
短腸症候群市場調査レポート:医薬品クラス別(GLP-2、グルタミン、成長ホルモン)-2026年までの予測-COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の短腸症候群の市場規模は、2020年の8億6,406万米ドルから、2025年末までに20億556万米ドルに拡大すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。アップデートされた調査では、COVID-19が市場に及ぼす影響を考慮し、洞察、分析、予測などを提供しています。

当レポートでは、短腸症候群市場について調査し、市場の概要とともに、医薬品クラス別、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 医薬品クラス別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 短腸症候群市場、医薬品クラス別

  • GLP-2
  • グルタミン
  • 成長ホルモン

第7章 南北アメリカの短腸症候群市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第8章 アジア太平洋地域の短腸症候群市場

  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第9章 欧州、中東・アフリカの短腸症候群市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第10章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第11章 企業のユーザビリティプロファイル

  • 9 Meters Biopharma, Inc.
  • Adocia SAS
  • Ardelyx Inc
  • AstraZeneca PLC
  • Emmaus Life Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mylan N.V.
  • Naia Pharmaceuticals, Inc.
  • Nestle S.A.,
  • Novartis International AG
  • Nutrinia Ltd
  • OPKO Health Inc.
  • OxThera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals Inc.
  • Sancilio & Company Inc
  • Shire PLC
  • Swedish Orphan Biovitrum AB
  • Teva Pharmaceutical Industries Ltd
  • VectivBio AG
  • Zealand Pharma A/S

第12章 付録

  • ディスカッションガイド
  • ライセンスと価格
  • 連絡先の詳細
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET: MARKET DYNAMICS
  • FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
  • FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2026
  • FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, 2018-2026 (USD MILLION)
  • FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 16. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 18. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 19. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 20. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 21. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 22. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 23. CALIFORNIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 24. FLORIDA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 25. ILLINOIS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 26. NEW YORK SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 27. OHIO SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 28. PENNSYLVANIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 29. TEXAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 30. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 31. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 33. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 34. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 42. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 44. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. GLOBAL SHORT BOWEL SYNDROME MARKET: FPNV POSITIONING MATRIX
  • FIGURE 56. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 57. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 58. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL SHORT BOWEL SYNDROME MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL SHORT BOWEL SYNDROME MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. CALIFORNIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. FLORIDA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. ILLINOIS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. NEW YORK SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. OHIO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. PENNSYLVANIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. TEXAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET: SCORES
  • TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET: BUSINESS STRATEGY
  • TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET: PRODUCT SATISFACTION
  • TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET: RANKING
  • TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY COMPANY, 2020
  • TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET: MERGER & ACQUISITION
  • TABLE 52. GLOBAL SHORT BOWEL SYNDROME MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 53. GLOBAL SHORT BOWEL SYNDROME MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 54. GLOBAL SHORT BOWEL SYNDROME MARKET: INVESTMENT & FUNDING
  • TABLE 55. GLOBAL SHORT BOWEL SYNDROME MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 56. GLOBAL SHORT BOWEL SYNDROME MARKET: LICENSE & PRICING
  • TABLE 57. GLOBAL SHORT BOWEL SYNDROME MARKET: CONTACT DETAILS
目次
Product Code: MRR-0309FBC5113F

The Global Short Bowel Syndrome Market size was estimated at USD 864.06 Million in 2020 and expected to reach USD 1,026.86 Million in 2021, at a Compound Annual Growth Rate (CAGR) 19.18% to reach USD 2,476.11 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Short Bowel Syndrome to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Class, the Short Bowel Syndrome Market was studied across GLP-2, Glutamine, and Growth Hormone.

Based on Geography, the Short Bowel Syndrome Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Short Bowel Syndrome Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Short Bowel Syndrome Market, including 9 Meters Biopharma, Inc., Adocia SAS, Ardelyx Inc, AstraZeneca PLC, Emmaus Life Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mylan N.V., Naia Pharmaceuticals, Inc., Nestle S.A.,, Novartis International AG, Nutrinia Ltd, OPKO Health Inc., OxThera AB, Pfizer Inc., PhaseBio Pharmaceuticals Inc., Sancilio & Company Inc, Shire PLC, Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd, VectivBio AG, and Zealand Pharma A/S.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Short Bowel Syndrome Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Short Bowel Syndrome Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Short Bowel Syndrome Market?
  • 4. What is the competitive strategic window for opportunities in the Global Short Bowel Syndrome Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Short Bowel Syndrome Market?
  • 6. What is the market share of the leading vendors in the Global Short Bowel Syndrome Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Short Bowel Syndrome Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Class Outlook
  • 3.4. Geography Outlook
  • 3.5. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased prevalence of short bowel syndrome and awareness programs by non-profit organizations
      • 5.1.1.2. Rising efforts in the launch of effective treatments
      • 5.1.1.3. Awareness Programs by Non-Profit Organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of approved treatment options
      • 5.1.2.2. Lethal adverse complications like colonic cancer, polyps along with common side effects associated with the medication
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of short bowel syndrome drugs is at a nascent stage
      • 5.1.3.2. Public-private partnerships are encouraging pharmaceutical companies to develop new orphan drugs for short bowel syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Awareness among physicians
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Short Bowel Syndrome Market, by Drug Class

  • 6.1. Introduction
  • 6.2. GLP-2
  • 6.3. Glutamine
  • 6.4. Growth Hormone

7. Americas Short Bowel Syndrome Market

  • 7.1. Introduction
  • 7.2. Argentina
  • 7.3. Brazil
  • 7.4. Canada
  • 7.5. Mexico
  • 7.6. United States
    • 7.6.1. California
    • 7.6.2. Florida
    • 7.6.3. Illinois
    • 7.6.4. New York
    • 7.6.5. Ohio
    • 7.6.6. Pennsylvania
    • 7.6.7. Texas

8. Asia-Pacific Short Bowel Syndrome Market

  • 8.1. Introduction
  • 8.2. China
  • 8.3. India
  • 8.4. Indonesia
  • 8.5. Japan
  • 8.6. Malaysia
  • 8.7. Philippines
  • 8.8. South Korea
  • 8.9. Thailand

9. Europe, Middle East & Africa Short Bowel Syndrome Market

  • 9.1. Introduction
  • 9.2. France
  • 9.3. Germany
  • 9.4. Italy
  • 9.5. Netherlands
  • 9.6. Qatar
  • 9.7. Russia
  • 9.8. Saudi Arabia
  • 9.9. South Africa
  • 9.10. Spain
  • 9.11. United Arab Emirates
  • 9.12. United Kingdom

10. Competitive Landscape

  • 10.1. FPNV Positioning Matrix
    • 10.1.1. Quadrants
    • 10.1.2. Business Strategy
    • 10.1.3. Product Satisfaction
  • 10.2. Market Ranking Analysis
  • 10.3. Market Share Analysis, By Quadrant
  • 10.4. Market Share Analysis, By Company
  • 10.5. Competitive Scenario
    • 10.5.1. Merger & Acquisition
    • 10.5.2. Agreement, Collaboration, & Partnership
    • 10.5.3. New Product Launch & Enhancement
    • 10.5.4. Investment & Funding
    • 10.5.5. Award, Recognition, & Expansion

11. Company Usability Profiles

  • 11.1. 9 Meters Biopharma, Inc.
  • 11.2. Adocia SAS
  • 11.3. Ardelyx Inc
  • 11.4. AstraZeneca PLC
  • 11.5. Emmaus Life Sciences, Inc.
  • 11.6. Johnson & Johnson Services, Inc.
  • 11.7. Merck KGaA
  • 11.8. Mylan N.V.
  • 11.9. Naia Pharmaceuticals, Inc.
  • 11.10. Nestle S.A.,
  • 11.11. Novartis International AG
  • 11.12. Nutrinia Ltd
  • 11.13. OPKO Health Inc.
  • 11.14. OxThera AB
  • 11.15. Pfizer Inc.
  • 11.16. PhaseBio Pharmaceuticals Inc.
  • 11.17. Sancilio & Company Inc
  • 11.18. Shire PLC
  • 11.19. Swedish Orphan Biovitrum AB
  • 11.20. Teva Pharmaceutical Industries Ltd
  • 11.21. VectivBio AG
  • 11.22. Zealand Pharma A/S

12. Appendix

  • 12.1. Discussion Guide
  • 12.2. License & Pricing
  • 12.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.